Evidence map›Paper›PMID 37116586›Full record

ArticleJournal of virological methods2023

Potential use of high-resolution melting analyses for SARS-CoV-2 genomic surveillance.

Adriana de Souza Andrade, Eduarda Fernandes Freitas, Emerson de Castro Barbosa, Natália Rocha Guimarães, Felipe Campos de Melo Iani, Alana Vitor Barbosa da Costa, André Felipe Leal Bernardes, Talita Emile Ribeiro Adelino, Ana Caroline Zampiroli Ataide, Tatiana Schäffer Gregianini and 7 more

Abstract read
In one paragraph

Article in Journal of virological methods, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Adriana de Souza AndradeServiço de Pesquisa em Doenças Infecciosas, Divisão de Ciência e Inovação, Fundação Ezequiel Dias, Belo Horizonte, MG, Brazil.
Eduarda Fernandes FreitasServiço de Pesquisa em Doenças Infecciosas, Divisão de Ciência e Inovação, Fundação Ezequiel Dias, Belo Horizonte, MG, Brazil; Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Emerson de Castro BarbosaServiço de Pesquisa em Doenças Infecciosas, Divisão de Ciência e Inovação, Fundação Ezequiel Dias, Belo Horizonte, MG, Brazil; Serviço de Virologia e Riquetsioses, Divisão de Epidemiologia e Controle de Doenças, Laboratório Central do Estado de Minas Gerais, Fundação Ezequiel Dias, Belo Horizonte, MG, Brazil.
Natália Rocha GuimarãesServiço de Virologia e Riquetsioses, Divisão de Epidemiologia e Controle de Doenças, Laboratório Central do Estado de Minas Gerais, Fundação Ezequiel Dias, Belo Horizonte, MG, Brazil.
Felipe Campos de Melo IaniServiço de Virologia e Riquetsioses, Divisão de Epidemiologia e Controle de Doenças, Laboratório Central do Estado de Minas Gerais, Fundação Ezequiel Dias, Belo Horizonte, MG, Brazil.
Alana Vitor Barbosa da CostaServiço de Virologia e Riquetsioses, Divisão de Epidemiologia e Controle de Doenças, Laboratório Central do Estado de Minas Gerais, Fundação Ezequiel Dias, Belo Horizonte, MG, Brazil.
André Felipe Leal BernardesServiço de Virologia e Riquetsioses, Divisão de Epidemiologia e Controle de Doenças, Laboratório Central do Estado de Minas Gerais, Fundação Ezequiel Dias, Belo Horizonte, MG, Brazil.
Talita Emile Ribeiro AdelinoServiço de Virologia e Riquetsioses, Divisão de Epidemiologia e Controle de Doenças, Laboratório Central do Estado de Minas Gerais, Fundação Ezequiel Dias, Belo Horizonte, MG, Brazil.
Ana Caroline Zampiroli AtaideServiço de Pesquisa em Doenças Infecciosas, Divisão de Ciência e Inovação, Fundação Ezequiel Dias, Belo Horizonte, MG, Brazil.
Tatiana Schäffer GregianiniLaboratório Central de Saúde Pública, Centro Estadual de Vigilância em Saúde da Secretaria de Saúde do Estado do Rio Grande do Sul (LACEN/CEVS/SES-RS), Porto Alegre, RS, Brazil.
Jônathas Dias NunesLaboratório Central Noel Nutels. Laboratório Central do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Lorenzzo Lyrio StringariLaboratório Central de Saúde Pública do Estado do Espírito Santo, Secretaria de Estado de Saúde do Espírito Santo, Vitória, ES, Brazil; Núcleo de Doenças Infecciosas, Universidade Federal do Espírito Santo, Vitória, ES, Brazil.
Irina Nastassja RiedigerDivisão dos Laboratórios de Epidemiologia e Controle de Doenças, Laboratório Central do Estado do Paraná, São José dos Pinhais, PR, Brazil.
Sandra Bianchini FernandesLaboratório Central de Saúde Pública do Estado de Santa Catarina, Florianópolis, SC, Brazil.
Ronaldo de JesusInstituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Coordenação-Geral de Laboratórios de Saúde Pública, Ministério da Saúde, Brasília, DF, Brazil.
Vagner FonsecaOrganização Pan-Americana da Saúde/Organização Mundial da Saúde, Brasília, DF, Brazil.
Sérgio CaldasServiço de Pesquisa em Doenças Infecciosas, Divisão de Ciência e Inovação, Fundação Ezequiel Dias, Belo Horizonte, MG, Brazil. Electronic address: sergio.caldas@funed.mg.gov.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pandemic caused by COVID-19 and the emergence of new variants of SARS-CoV-2 have generated clinical and epidemiological impacts on a global scale. The use of strategies for monitoring viral circulation and identifying mutations in genomic regions involved in host interaction are important measures to mitigate viral dissemination and reduce its likely complications on population health. In this context, the objective of this work was to explore the potential of high-resolution melting (HRM) analysis combined with one-step real-time reverse transcription PCR in a closed-tube system, as a fast and convenient method of screening for SARS-CoV-2 mutations with possible implications on host-pathogen interactions. The HRM analyses allowed the distinction of the Gamma, Zeta, Alpha, Delta, and Omicron variants against the predecessors (B.1.1.28, B.1.1.33) of occurrence in Brazil. It is concluded that the molecular tool standardized here has the potential to optimize the genomic surveillance of SARS-CoV-2, and could be adapted for genomic surveillance of other pathogens, due to its ability to detect, prior to sequencing, samples suggestive of new variants, selecting them more assertively and earlier for whole genome sequencing when compared to random screening.

Indexed as

COVID-19SARS-CoV-2GenomicsHumansMutationReal-Time Polymerase Chain ReactionCOVID-19Genomic sequencingHRMSARS-CoV-2Variants

Identifiers

PMID37116586
PMCPMC10132831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.